Addenda Capital Inc. Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Addenda Capital Inc. raised its stake in Pfizer Inc. (NYSE:PFEFree Report) by 29.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 198,325 shares of the biopharmaceutical company’s stock after purchasing an additional 45,380 shares during the period. Addenda Capital Inc.’s holdings in Pfizer were worth $5,710,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Denver Wealth Management Inc. grew its position in shares of Pfizer by 3.8% during the fourth quarter. Denver Wealth Management Inc. now owns 12,908 shares of the biopharmaceutical company’s stock worth $372,000 after acquiring an additional 467 shares during the last quarter. Colonial River Wealth Management LLC grew its position in shares of Pfizer by 33.5% during the fourth quarter. Colonial River Wealth Management LLC now owns 38,168 shares of the biopharmaceutical company’s stock worth $1,099,000 after acquiring an additional 9,572 shares during the last quarter. Physician Wealth Advisors Inc. grew its position in shares of Pfizer by 5.1% during the fourth quarter. Physician Wealth Advisors Inc. now owns 10,571 shares of the biopharmaceutical company’s stock worth $299,000 after acquiring an additional 509 shares during the last quarter. Benchmark Financial Wealth Advisors LLC purchased a new position in shares of Pfizer during the fourth quarter worth approximately $235,000. Finally, Black Swift Group LLC purchased a new position in shares of Pfizer during the fourth quarter worth approximately $288,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Barclays lowered their price objective on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 14th. Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $36.88.

View Our Latest Research Report on Pfizer

Pfizer Price Performance

Pfizer stock opened at $27.55 on Wednesday. Pfizer Inc. has a one year low of $25.61 and a one year high of $42.22. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The business has a fifty day moving average of $27.43 and a two-hundred day moving average of $29.29. The company has a market cap of $156.00 billion, a P/E ratio of 76.53, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFEGet Free Report) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter last year, the company earned $1.14 earnings per share. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. As a group, analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.